Hypothalamic-chiasmatic tumours account for 5-10% of CNS tumours in children and can compromise hypothalamic function, causing alterations in energy balance and weight gain. In inoperable cases, chemotherapy and radiotherapy are used; the latter, although the gold standard, is associated with significant neurocognitive and endocrine-metabolic side effects, proportional to the hypothalamic damage. The ketogenic diet, used for decades in the treatment of drug-resistant childhood epilepsy, induces the use of ketone bodies as a source of energy for the brain and is effective in controlling seizures. Among the different variants, the modified Atkins diet was chosen in this study to promote better patient adherence. This study aims to evaluate the effectiveness of the ketogenic diet (KD) in treating central obesity secondary to hypothalamic-chiasmatic tumours (gliomas, craniopharyngiomas, germ cell tumours, etc.), which often lead to excessive weight gain. This is refractory to drug therapy and lifestyle changes, such as low-calorie diets and exercise.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Atkins Modified Diet (MAD)
Meyer Children's Hospital IRCCS
Florence, Florence, Italy
RECRUITINGPercentage of patients who experience weight loss of at least 5% over 24 months
Time frame: From enrollment to the end of the follow up period at 24 months
Percentage of patients showing weight reduction, improvement in lipid and carbohydrate parameters
Time frame: From enrollment to the end of the follow up period at 24 months
Percentage of patients with ketosis
Time frame: From enrollement to the end of the follow up period at 24 months
Percentage of patients with serious adverse events
Time frame: From enrollement to the end of the follow up period at 24 months
Adherence rate to the proposed dietary intervention, considering the number of patients who discontinue the diet and those who continue it
Time frame: From enrollment to the end of the follow up at 24 months
Percentage of patients showing reduction of lean body mass in 24 months
Time frame: From enrollment to the end of the follow up period at 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.